



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#53201

**Date:** September 15, 2023

**Subject:** CDAKQ Options - Expiration Pricing Consideration

CDAKQ (Codiak BioSciences, Inc. options) will be subject to special pricing consideration in expiration processing on September 15, 2023. The pricing consideration is due to the unknown option deliverable of CDAKQ as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

#### **CDAKQ**

CDAKQ options are Codiak BioSciences, Inc. options, adjusted on July 7, 2023 (see OCC Information Memo #52792). The deliverable of CDAKQ options is:

#### **NEW DELIVERABLE**

**PER CONTRACT:** 100 x the pro rata portion of future distributions received by CDAKQ shareholders, if any

As of September 15, 2023, the CDAKQ Exchange Agent has not determined the pro rata portion of future distributions, if any, received by CDAKQ shareholders, applicable in the bankruptcy.

For purposes of calculating CDAKQ price for use in expiration processing, OCC will use the closing price from the last day of trading, July 6, 2023, of \$0.00.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).